Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third international stroke trial)

Stroke

Volumn 45, Issue 12, 2014, Pages 3612-3617

  Whiteley, William N ^a   Thompson, Douglas ^b   Murray, Gordon ^b   Cohen, Geoff ^a   Lindley, Richard I ^c   Wardlaw, Joanna ^a,d   Sandercock, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Neuroimaging Sciences   (United Kingdom)

Author keywords

Mortality; Randomized controlled trial; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; ASSESSMENT OF HUMANS; BRAIN ISCHEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OXFORD COMMUNITY STROKE PROJECT SCALE; OXFORD HANDICAP SCALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; VERY ELDERLY; ADULT; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; STROKE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84924034778     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006890     Document Type: Article

References (15)

1. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;379:2352-2363.
2. IST-3 Collaborative Group. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third international stroke trial [ist-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013;12:768-776
3. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364-2372.
4. Bruins Slot K, Berge B, Dorman P, Lewis S, Dennis M, Sandercock P. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. 2008;336:376.
5. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [ist-3]): a randomised controlled trial. Lancet. 2012;379:2352-2363.
6. Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, et al; IST-3 Collaborative Group. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials. 2011;12:252.
7. IST-3 Collaborative Group. Statistical analysis plan for the third international stroke trial (ist-3); part of a thread of reports of the trial. Int J Stroke. 2012;7:186-187.
8. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project-1981-86.
9. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990;53:16-22.
10. Summary of product characteristics (alteplase). http://www.medicines. org.uk/emc/medicine/308/SPC/actilyse/. Accessed March 17, 2014.
11. König IR, Ziegler A, Bluhmki E, Hacke W, Bath PM, Sacco RL, et al.; Virtual International Stroke Trials Archive (VISTA) Investigators. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke. 2008;39:1821-1826.
12. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364-2372.
13. Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke. 2012;43:1691-1694.
14. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:1781-1787.
15. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904-2909.